Allspring中小型核心主动型ETF ASCE 深 沪
等待开盘 05-14 09:30:00 美东时间
32.08
-0.140
-0.43%
华盛通- 最 高32.35
- 今 开32.13
- 成交量 2.17万股
- 最 低 31.78
- 昨 收 32.22
- 总市值 6804.17万
- 52周最高 32.97
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 24.0619
- 委 比 25.00%
- 总股本 212.10万
- 历史最高 32.97
- 量 比 0.61
- 振 幅 1.77%
- 历史最低 24.0619
- 每 手 1
- 风险率 1.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADMA Biologics Earnings Call: ASCENIV Fuels Profits
ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the mai...
05-08 10:24
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
ADMA Biologics (ADMA) declined more than 17% on Thursday after the company lowered its full-year outlook and withdrew its long-term guidance, citing “uncertainty in the competitive landscape”. The sto...
05-08 00:17
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang ** Microsoft MSFT.O said on Weds that Azure cloud revenue would beat Wall St forecasts and announced $190 bln in capital spending for 2026, exceeding expectations ** Shares down 1.1% premarket AZURE ASCENDS ** Citigroup
04-30 16:24
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
04-22 19:15
BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing
BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing March 30 (Reuters) - SEC Filing: OUR BOND INC - ENTERS AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT WITH ASCENT ON MARCH 29, 2026 - SEC FILING OUR BOND, INC. - 8-K OUR BOND INC
03-30 21:26
ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today responded to a
03-27 19:08
ADMA Biologics drops amid short report from Culper Research
ADMA Biologics (ADMA) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics (ADMA). ADMA (ADMA) didn't immediately respond to Seeking ...
03-25 02:44
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million Hepion reported no revenue for FY 2025 and posted a net loss of USD 8.28 million, narrowing 37% year over year. Loss from operations was USD 4.16 million, narrowing 78%, as research an
03-12 18:07
Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on
03-02 21:16
